stockportfolio.pro
Vir Biotechnology, Inc. P/E Ratio 2017–2025
Vir Biotechnology, Inc. (VIR) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -5.7%/yr over 8 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | — | — |
| FY 2024 | — | — |
| FY 2023 | — | — |
| FY 2022 | 6.61 | -37.5% |
| FY 2021 | 10.57 | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
Source: Vir Biotechnology, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Vir Biotechnology, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeVir Biotechnology, Inc. — frequently asked questions
What is Vir Biotechnology, Inc.'s price-to-earnings ratio?
Vir Biotechnology, Inc. (VIR) reported price-to-earnings ratio of 6.61 for fiscal year 2022, per its SEC filings.
How has Vir Biotechnology, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2017 and 2025, VIR's price-to-earnings ratio declined at roughly 5.7% per year (compound annual rate), from 10.57 to 6.61.
Where does this data come from?
Figures are computed from Vir Biotechnology, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.